Recent Updates
Recently added Catalysts

TX002100

Phase 1

Hereditary Hemorrhagic Telangiectasia (HHT) | Monoclonal antibody | Other |Tectonic Therapeutic, Inc. Common Stock|Trials Updated: Oct 7, 2026

TX002100 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

TX002100 clinical trials

TX002100 · 1 trial · 1 indication

Phase 1 1
NCT07863609Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)
NOT YET_RECRUITING20 Analytics
PHASE1NOT YET_RECRUITING
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
NCT0786360920
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of adverse events (AEs), including serious adverse events (SAEs)
Screening up to Day 225
Incidence of clinically significant changes from baseline in safety laboratory assessments and other safety assessments
Baseline up to Day 225

Secondary Endpoints

To assess hematologic support score change from baseline calculated over the 12 weeks preceding the time point
Baseline up to 6 months
To assess hematologic impact score
Measured at 6 months
To assess hemoglobin change from baseline
Baseline up to 6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TX002100EXPERIMENTALParticipants will receive subcutaneous (SC) injection of TX002100 administered weekly.

Interventions

NameTypeDescription
TX002100BIOLOGICALSubcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: 1. Adults with HHT who need regular intravenous iron or blood transfusions. 2. Females of childbearing potential and male participants must agree to comply with the contraception requirements. 3. Able to understand and is willing and able to comply with the study requirements an...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 7, 2026NCT07863609NEW_TRIAL: changed
LOWOct 7, 2026NCT07863609NEW_TRIAL: changed

Explore more on BiopharmaWatch

Tectonic Therapeutic, Inc. Common Stock (TECX)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with TCompanies A to ZEvery biotech and pharma company we track